MCID: LMY002
MIFTS: 51

Leiomyoma

Categories: Cancer diseases, Muscle diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leiomyoma

MalaCards integrated aliases for Leiomyoma:

Name: Leiomyoma 11 75 53 43 14
Leiomyomatous Neoplasm 11
Leiomyomatous Tumor 11
Uterine Fibroids 71
Fibroid Tumor 71
Leiomyomas 14

Classifications:



External Ids:

Disease Ontology 11 DOID:127
MeSH 43 D007889
NCIt 49 C3157
SNOMED-CT 68 1162890002
UMLS 71 C0023267 C0042133

Summaries for Leiomyoma

Disease Ontology: 11 A cell type benign neoplasm that is a benign tumor of smooth muscle cells.

MalaCards based summary: Leiomyoma, also known as leiomyomatous neoplasm, is related to bizarre leiomyoma and leiomyoma, uterine, and has symptoms including pelvic pain An important gene associated with Leiomyoma is HMGA2 (High Mobility Group AT-Hook 2), and among its related pathways/superpathways are Nuclear receptors and TGF-beta Signaling Pathways. The drugs Cetrorelix and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, uterus and small intestine, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and homeostasis/metabolism

Wikipedia: 75 A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer... more...

Related Diseases for Leiomyoma

Diseases related to Leiomyoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1016)
# Related Disease Score Top Affiliating Genes
1 bizarre leiomyoma 33.0 PGR FH ESR1
2 leiomyoma, uterine 32.7 RAD51B PGR HMGA2 GNRH1 FH ESR2
3 leiomyoma cutis 32.5 FH COL4A6
4 liver leiomyoma 32.3 PGR ESR1 CD34
5 prostate leiomyoma 32.3 GNRH1 CD34
6 subserous uterine fibroid 32.2 PGR CYP19A1
7 vagina leiomyoma 32.2 PGR CD34
8 cellular leiomyoma 32.2 PGR MME
9 leiomyosarcoma 32.1 VIM S100A1 PGR HMGA2 FH ESR1
10 dartoic leiomyoma 32.1 FH CD34
11 colon leiomyoma 31.9 HMGA2 FH COL4A6 COL4A5 CD34
12 breast leiomyoma 31.8 PGR MME FH
13 leiomyomatosis 31.7 VIM PGR GNRH1 FH ESR1 DES
14 vulvar leiomyoma 31.5 PGR MME HMGA2 ESR1 CD34
15 uterus leiomyosarcoma 31.2 PGR HMGA2 FH DES ACTC1
16 endometriosis 31.1 PGR GNRH1 ESR2 ESR1 CYP19A1
17 ovarian cyst 30.9 PGR GNRH1 ESR2 ESR1 CYP19A1
18 lymphangioleiomyomatosis 30.8 PGR GNRH1 ESR1 DES
19 mesenchymal cell neoplasm 30.8 MME HMGA2 CD34
20 vaginal discharge 30.8 PGR GNRH1 ESR1 CYP19A1
21 lipomatosis, multiple 30.8 S100A1 HMGA2 DES CD34
22 gastrointestinal stromal tumor 30.8 VIM S100A1 FH ESR1 DES CD34
23 infertility 30.7 PGR GNRH1 ESR2 ESR1 CYP19A1
24 myoma 30.7 PGR MME HMGA2 GNRH1 FH ESR1
25 fibroma 30.7 VIM S100A1 PGR ESR1 DES CD34
26 neurilemmoma 30.7 VIM S100A1 DES CD34 ACTC1
27 uterine sarcoma 30.6 MME ESR1 DES CYP19A1
28 endometrial hyperplasia 30.6 PGR ESR2 ESR1 CYP19A1
29 hemangioma 30.6 VIM PGR ESR1 CD34 ACTC1
30 pneumothorax 30.6 VIM PGR GNRH1 DES ACTC1
31 diffuse peritoneal leiomyomatosis 30.5 PGR GNRH1 ESR1 CYP19A1 CD34
32 fibromatosis 30.5 VIM DES ACTC1
33 breast lobular carcinoma 30.5 PGR ESR1 CYP19A1
34 neurofibroma 30.5 VIM S100A1 CD34 ACTC1
35 granular cell tumor 30.5 VIM S100A1 PGR DES
36 liposarcoma 30.4 VIM HMGA2 DES CD34
37 hemangiopericytoma, malignant 30.4 VIM DES CD34 ACTC1
38 angiosarcoma 30.4 VIM CD34 ACTC1
39 pleomorphic adenoma 30.4 VIM S100A1 HMGA2 DES ACTC1
40 smooth muscle tumor 30.4 VIM S100A1 PGR MME HMGA2 ESR1
41 teratoma 30.3 VIM ESR1 ACTC1
42 desmoid tumor 30.3 ESR1 DES CD34 ACTC1
43 sertoli-leydig cell tumor 30.3 VIM PGR DES
44 leydig cell tumor 30.3 GNRH1 ESR1 CYP19A1
45 endometriosis of ovary 30.2 PGR GNRH1 ESR2 ESR1 CYP19A1
46 gynecomastia 30.2 PGR GNRH1 ESR2 ESR1 CYP19A1
47 intravenous leiomyomatosis 30.2 PGR MME HMGA2 ESR1 COL4A6 CD34
48 glomus tumor 30.2 VIM S100A1 DES CD34 ACTC1
49 cryptorchidism, unilateral or bilateral 30.1 GNRH1 ESR2 ESR1 CYP19A1
50 breast disease 30.1 PGR ESR2 ESR1 CYP19A1

Graphical network of the top 20 diseases related to Leiomyoma:



Diseases related to Leiomyoma

Symptoms & Phenotypes for Leiomyoma

UMLS symptoms related to Leiomyoma:


pelvic pain

GenomeRNAi Phenotypes related to Leiomyoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ACTC1 CD34 COL4A5 COL4A6 COX6C CYP19A1
2 no effect GR00402-S-2 10.2 ACTC1 CD34 COL4A5 COL4A6 COX6C CYP19A1
3 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 ESR1 ESR2 FH RAD51B

MGI Mouse Phenotypes related to Leiomyoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ACTC1 CD34 COL4A5 CYP19A1 DES ESR1
2 normal MP:0002873 10.07 ACTC1 COL4A6 CYP19A1 ESR1 ESR2 GNRH1
3 cellular MP:0005384 10 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
4 muscle MP:0005369 9.92 ACTC1 CYP19A1 DES ESR1 ESR2 PGR
5 behavior/neurological MP:0005386 9.73 ACTC1 CYP19A1 DES ESR1 ESR2 HMGA2
6 integument MP:0010771 9.28 CD34 CYP19A1 DPT ESR1 ESR2 GNRH1

Drugs & Therapeutics for Leiomyoma

Drugs for Leiomyoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887
2
Ethanol Approved Phase 4 64-17-5 702
3
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
4
Calcium carbonate Approved, Investigational Phase 4 471-34-1
5
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Ferrous fumarate Approved Phase 4 141-01-5
7
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
8
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
9
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
10
Mecobalamin Approved, Investigational Phase 4 13422-55-4
11
Zinc oxide Approved Phase 4 1314-13-2
12
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
13
Tocopherol Approved, Investigational Phase 4 1406-66-2
14
Metyrosine Approved Phase 4 672-87-7 441350
15
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432
16
Remifentanil Approved Phase 4 132875-61-7 60815
17
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109
18
Plasminogen Approved Phase 4 9001-91-6
19
Prilocaine Approved Phase 4 721-50-6 4906
20
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
21
Misoprostol Approved Phase 4 59122-46-2 5282381
22
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
23
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
24
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
25
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
26
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
27
Relugolix Approved, Investigational Phase 4 737789-87-6 10348973
28
Goserelin Approved Phase 4 65807-02-5 5311128 47725
29
Tranexamic acid Approved Phase 4 1197-18-8 5526
30
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
31
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
32
Desogestrel Approved Phase 4 54024-22-5 40973
33
Dienogest Approved Phase 4 65928-58-7 13175121 68861
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
37
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
38
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
39
Beta carotene Approved, Nutraceutical Phase 4 6811-73-0, 7235-40-7 10256668 5280489
40
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
41
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
42
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
43
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
46
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
47
Cobalamin Experimental Phase 4 13408-78-1 6857388
48
Fibrinolysin Investigational Phase 4 9004-09-5
49 Prolactin Release-Inhibiting Factors Phase 4
50 Hypnotics and Sedatives Phase 4

Interventional clinical trials:

(show top 50) (show all 395)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
2 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
3 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
4 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Unknown status NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
5 Ulipristal Versus Gonadotropin-releasing Hormone Agonists Prior to Laparoscopic Myomectomy: a Double Blind Randomized Controlled Trial Unknown status NCT02288130 Phase 4 GnRHa;Ulipristal
6 Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Unknown status NCT04364581 Phase 4 Letrozole;Placebo
7 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
8 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
9 Use of Oxytocin in MRI-HIFU Treatment Unknown status NCT03937401 Phase 4 Oxytocin
10 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
11 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
12 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
13 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
14 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
15 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
16 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
17 Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy: a Randomized Controlled Trial Completed NCT04482959 Phase 4 Carbetocin;Sodium chloride 0.9%
18 A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03886220 Phase 4 Elagolix;Placebo
19 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Completed NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
20 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
21 Ulipristal Acetate Therapy Versus Uterine Artery Embolization in Management of Uterine Fibroids Completed NCT04832906 Phase 4 Ulipristal Oral Tablet
22 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
23 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
24 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
25 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
26 Deep Sedation in Spontaneously Breathing Patients Combined With Local Anesthesia Versus General Anesthesia in Gynecological Patients at Same Day Surgical at Hospitalsenheden Horsens Completed NCT01412632 Phase 4 Remifentanil, propofol and citanest
27 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
28 Effect of Transversus Abdominal Plane Block Using Liposomal Bupivacaine Versus Standard Bupivacaine for Open Myomectomy: A Prospective Randomized Control Trial Recruiting NCT04272086 Phase 4 Bupivacaine;Bupivacaine liposome;normal saline
29 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
30 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
31 Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial. Not yet recruiting NCT05538689 Phase 4 Myfembree Oral Product
32 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Terminated NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
33 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
34 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
35 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
36 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Terminated NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
37 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
38 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
39 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
40 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
41 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
42 Effect of Dexmedetomidine on Stress Study of Pituitrin in Laparoscopic Hysteromyoma Surgery Unknown status NCT03524950 Phase 3 Dexmedetomidine
43 Multicenter, Randomized Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids (MRgFUS TUF) Compared to Myomectomy in Symptomatic Medication and Not Sufficiently Treatable Uterine Fibroids Unknown status NCT03948789 Phase 3
44 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Unknown status NCT02942537 Phase 2, Phase 3
45 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Unknown status NCT03483142 Phase 3 Misoprostol;Placebos
46 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
47 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
48 An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Completed NCT03751124 Phase 3 Relugolix;Estradiol/norethindrone acetate;Placebo for relugolix;Placebo for E2/NETA
49 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147197 Phase 3 Ulipristal acetate (UPA);Placebo
50 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147158 Phase 3 Ulipristal acetate (UPA);Placebo

Search NIH Clinical Center for Leiomyoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Leuprolide
Leuprolide Acetate

Cochrane evidence based reviews: leiomyoma

Genetic Tests for Leiomyoma

Anatomical Context for Leiomyoma

Organs/tissues related to Leiomyoma:

MalaCards : Smooth Muscle, Uterus, Small Intestine, Breast, Endothelial, Liver, Prostate

Publications for Leiomyoma

Articles related to Leiomyoma:

(show top 50) (show all 13166)
# Title Authors PMID Year
1
Progesterone is essential for maintenance and growth of uterine leiomyoma. 53 62
20375184 2010
2
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 53 62
20414849 2010
3
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. 53 62
19464003 2010
4
Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. 53 62
20414841 2010
5
Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. 53 62
19328471 2010
6
Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. 53 62
20437637 2010
7
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. 53 62
19906824 2010
8
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 53 62
20124487 2010
9
Mayer-Rokitansky-Kustner Hauser syndrome complicated by either uterine leiomyoma or ovarian tumor. 53 62
20178550 2010
10
Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. 53 62
19741209 2010
11
Association of N-terminal pro B-type natriuretic peptide and sex hormone-binding globulin in non-obese peri- and postmenopausal women. 53 62
19945451 2010
12
MIB-1 (Ki-67), estrogen receptor, progesterone receptor, and p53 expression in atypical cells in uterine symplastic leiomyomas. 53 62
19952937 2010
13
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 53 62
19135657 2010
14
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 53 62
19700613 2009
15
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 53 62
19808856 2009
16
Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. 53 62
19851199 2009
17
Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma. 53 62
19602040 2009
18
A leiomyoma presenting as an exophytic periurethral mass: a case report and review of the literature. 53 62
19573833 2009
19
Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. 53 62
19179429 2009
20
High aromatase expression in uterine leiomyoma tissues of African-American women. 53 62
19240151 2009
21
Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. 53 62
19176543 2009
22
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 53 62
19151755 2009
23
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole. 53 62
18523791 2009
24
Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. 53 62
18980243 2009
25
[Acute abdomen for perforated gastrointestinal stromal tumor (GIST). A case report]. 53 62
19537128 2009
26
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 53 62
18249392 2009
27
Genistein suppresses spontaneous oviduct tumorigenesis in quail. 53 62
20155619 2009
28
Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk. 53 62
18691687 2008
29
Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. 53 62
18853184 2008
30
Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. 53 62
18166184 2008
31
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 53 62
19012097 2008
32
Treatment of symptomatic uterine leiomyoma with letrozole. 53 62
18854113 2008
33
Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience. 53 62
18710984 2008
34
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 53 62
18701604 2008
35
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 53 62
18565690 2008
36
Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic ultrasonography. 53 62
18505417 2008
37
[Fibroblast growth factor gene expression in uterine leiomyomas]. 53 62
18819464 2008
38
Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. 53 62
18580309 2008
39
Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors. 53 62
18425046 2008
40
Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer. 53 62
18503824 2008
41
Differential metabolic consequences of fumarate hydratase and respiratory chain defects. 53 62
18313410 2008
42
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. 53 62
18448745 2008
43
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). 53 62
18164802 2008
44
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 53 62
18403645 2008
45
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 53 62
18281245 2008
46
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. 53 62
18216291 2008
47
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. 53 62
18182446 2008
48
[Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors]. 53 62
18359707 2008
49
Expression of sex hormone-binding globulin, oxytocin receptor, caveolin-1 and p21 in leiomyoma. 53 62
17952758 2008
50
Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. 53 62
19083394 2008

Variations for Leiomyoma

Expression for Leiomyoma

Search GEO for disease gene expression data for Leiomyoma.

Pathways for Leiomyoma

GO Terms for Leiomyoma

Cellular components related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen type IV trimer GO:0005587 8.92 COL4A6 COL4A5

Biological processes related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estrogen GO:0043627 9.73 TGFB3 MME ESR1
2 paracrine signaling GO:0038001 9.46 PGR CD34
3 mammary gland development GO:0030879 9.35 TGFB3 PGR CYP19A1
4 intracellular steroid hormone receptor signaling pathway GO:0030518 9.1 PGR ESR2 ESR1

Molecular functions related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear receptor activity GO:0004879 9.8 PGR ESR2 ESR1
2 steroid binding GO:0005496 9.63 PGR ESR2 ESR1
3 estrogen response element binding GO:0034056 9.56 ESR2 ESR1
4 nuclear estrogen receptor activity GO:0030284 9.26 ESR2 ESR1
5 nuclear steroid receptor activity GO:0003707 9.02 PGR ESR2 ESR1

Sources for Leiomyoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....